On Friday, Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) was -3.69% drop from the session before settling in for the closing price of $27.88. A 52-week range for CRNX has been $24.10 – $62.53.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -12.11%. When this article was written, the company’s average yearly earnings per share was at -28.88%. With a float of $87.18 million, this company’s outstanding shares have now reached $94.13 million.
The extent of productivity of a business whose workforce counts for 437 workers is very important to gauge. In terms of profitability, gross margin is 0.92%, operating margin of -49569.74%, and the pretax margin is -43191.05%.
Crinetics Pharmaceuticals Inc (CRNX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Crinetics Pharmaceuticals Inc stocks. The insider ownership of Crinetics Pharmaceuticals Inc is 7.43%, while institutional ownership is 104.19%. The most recent insider transaction that took place on Jun 12 ’25, was worth 3,141,877. In this transaction Chief Scientific Officer of this company sold 97,483 shares at a rate of $32.23, taking the stock ownership to the 99,713 shares. Before that another transaction happened on Jun 12 ’25, when Company’s Officer proposed sale 97,483 for $32.33, making the entire transaction worth $3,151,625.
Crinetics Pharmaceuticals Inc (CRNX) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.96 earnings per share (EPS) during the time that was less than consensus figure (set at -0.91) by -0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -28.88% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -2.42% during the next five years compared to -12.11% drop over the previous five years of trading.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Trading Performance Indicators
You can see what Crinetics Pharmaceuticals Inc (CRNX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 17.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1819.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.11, a number that is poised to hit -1.22 in the next quarter and is forecasted to reach -4.98 in one year’s time.
Technical Analysis of Crinetics Pharmaceuticals Inc (CRNX)
The latest stats from [Crinetics Pharmaceuticals Inc, CRNX] show that its last 5-days average volume of 1.39 million was superior to 0.95 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 20.44%.
During the past 100 days, Crinetics Pharmaceuticals Inc’s (CRNX) raw stochastic average was set at 22.27%, which indicates a significant increase from 17.99% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.37 in the past 14 days, which was lower than the 1.49 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $30.60, while its 200-day Moving Average is $39.10.
